

**Institutional Biosafety Committee
Icahn School of Medicine at Mount Sinai**

MEETING MINUTES

MEETING DETAILS	
Meeting Date	August 21, 2025
Meeting Time	2:30 PM - 3:30 PM
Meeting Type	Videoconference
Call to Order	2:32 PM
Adjournment	3:30 PM
Conflicts of Interest	Biosafety Director and Biosafety Officer submitted 1 registration. Both members were recused from reviewing and voting on the submission.

ATTENDANCE	
Name	Present
V. SIMON (Chair; Scientist)	No
B. LEE (Vice-Chair; Scientist)	Yes
R. ALBRECHT (Biological Safety Officer)	Yes
T. BANIA (Human Gene Therapy)	No
R. BRODY (Scientist)	Yes
L. CHAUHAN (Biological Safety Officer)	Yes
J. COHEN (Veterinarian)	Yes
H. DONG (Human Gene Therapy)	Yes
D. D'SOUZA (Employee Health)	Yes
C. NAPIER (Employee Health)	Yes
J. OCHANDO (Scientist)	No
C. SHOR (Local Non-affiliated)	Yes
S. STRAUSS (Legal Counsel)	No
N. TZAVARAS (Scientist)	Yes
S. PATIL (Administrative)	No
S. ROSA (Administrative)	Yes

QUORUM
The IBC has 12 voting members. 7 members are required to conduct business. 10 members were present. Quorum was met.

OTHER INDIVIDUALS IN ATTENDANCE	
None	

REVIEW OF PRIOR MEETING MINUTES	
Date of meeting minutes	June 26, 2025
Motion	To approve the minutes as written
Votes	(8) For (0) Against (2) Abstain
Result	Approved for posting

REVIEW OF PRIOR MEETING MINUTES	
Date of meeting minutes	July 17 2025
Motion	To approve the minutes as written
Votes	(7) For (0) Against (3) Abstain
Result	Minor modifications required before posting

REVIEW OF PRIOR BUSINESS	
Review of [REDACTED]Lab: Modifications Required for Standard 3-Year Approval	
Description	From July 17, 2025 Meeting: The [REDACTED] Lab completed IBC and Biosafety Program modification requests. eSafety registration was approved for standard 3-year term.

COMMITTEE REVIEW SUBMISSIONS

1. De Novo Review

Investigator Name(s):	ELVIN WAGENBLAST
Registration Title:	SPROTO202500000082
Submission ID:	SAMENDCR202500000065
Submission Type:	Characterization of Blood Stem Cells and Leukemia
Project Overview	Research team investigates how normal blood stem cells can become cancerous. Their approach focuses on characterization of normal and leukemic human stem cells using xenotransplantation and on experimental models of leukemic transformation and progression created by introducing mutations in normal stem cells using CRISPR/Cas9-mediated genome engineering or transducing genes in normal stem cells using lentiviral vectors.
NIH Guidelines Section	III-D-3 III-D-3-a
Risk Assessment and Discussion	Research activities includes handling of experimental mice, sharps, lentivirus (3 rd gen) and CRISPR/Cas9. The registration and lab SOPs include required PPE, handling guidelines, Waste Management and Spill Response.
Training	No deficiencies were noted in staff training records.
Occupational Health Representative review	NA
Biosafety Level Assignment	BL2; BL2N
Highest BSL Practices:	BSL-2
Highest ABSL Practices:	ABSL-2
IBC Vote	Motion: Approve after completion of minor, administrative modifications Votes: <ul style="list-style-type: none"> • (10) For • (0) Against • (0) Abstain • Conflict(s) of Interest: None.

2. Initial Protocol

Investigator Name(s):	RANDY ALBRECHT
Registration Title:	SPROTO202500000084
Submission ID:	SAMENDCR202500000065
Submission Type:	ISMMS SATP
Project Overview	This research registration provides an administrative overview of the ISMMS Select Agents and Toxins Program. The registration lists all active PIs, laboratorians, and Support Role staff. The purpose of this research registration is not to document specific work objectives, but to provide the IBC and the IBSP, an annual review of the entity's select agents and toxins program and compliance of the enrolled staff with regulatory training requirements.
NIH Guidelines Section	III-D-3 III-D-3-a
Risk Assessment and Discussion	Research activities includes handling of experimental mice, sharps, lentivirus (3 rd gen) and CRISPR/Cas9. The registration and lab SOPs include required PPE, handling guidelines, Waste Management and Spill Response.
Training	Some listed staff require updated trainings.
Occupational Health Representative review	Confirmation of completion of OHSQ by all members in process.
Biosafety Level Assignment	BL3
Highest BSL Practices:	BSL-3
Highest ABSL Practices:	ABSL-3
IBC Vote	Motion: Approve after completion trainings and OHSQ confirmation for listed team members. Votes: <ul style="list-style-type: none"> • (8) For • (0) Against • (0) Abstain • Conflict(s) of Interest: Biosafety Director and BSO.

OTHER AGENDA ITEMS

New Business/Additional Topics

Nothing to report

Review of Incidents

Nothing to report

Inspections / Ongoing Oversight
--

Nothing to report

IBC Training

None

Public Comments

There were no public comments
